6533b829fe1ef96bd12896dd
RESEARCH PRODUCT
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.
Susana Rosello KeranenGuillem ArgilesRodrigo DienstmannAndrés CervantesNiels Jorgen Ostergaard SkartvedUlla H. HansenStephan BraunMarta Benavent ViñualesRocio Garcia CarboneroIvan D. Horaksubject
Cancer ResearchCetuximabColorectal cancermedicine.drug_classbusiness.industrymedicine.diseaseMonoclonal antibodymedicine.disease_causedigestive system diseasesOncologymedicineCancer researchPanitumumabIn patientKRASAnti-EGFR Monoclonal Antibodybusinessneoplasmsmedicine.drugdescription
3551 Background: Preclinical models suggest that WT KRAS mCRC may retain EGFR dependency despite resistance developed to anti-EGFR mAb treatment (eg, cetuximab or panitumumab). Sym004 is the first-...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |